Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
More Information Supplier PageFruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
More Information Supplier PageVoruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PageVoruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PageVoruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
More Information Supplier PageLevomilnacipran HCl is an antidepressant approved for the treatment of major depressive disorder in the United States.
More Information Supplier PageLevomilnacipran HCl is an antidepressant approved for the treatment of major depressive disorder in the United States.
More Information Supplier PageLevomilnacipran HCl is an antidepressant approved for the treatment of major depressive disorder in the United States.
More Information Supplier PageAMG 232 is a highly potent, selective and orally bioavailable piperidinone inhibitor of the MDM2-p53 interaction((SPR KD= 0.045 nM, SJSA-1 EdU IC50=9.1 nM).
More Information Supplier PageAMG 232 is a highly potent, selective and orally bioavailable piperidinone inhibitor of the MDM2-p53 interaction((SPR KD= 0.045 nM, SJSA-1 EdU IC50=9.1 nM).
More Information Supplier Page
